Published in Am J Physiol Gastrointest Liver Physiol on May 01, 2006
American Gastroenterological Association technical review on constipation. Gastroenterology (2013) 3.27
Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci (2012) 1.61
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol (2008) 1.54
A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.35
Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther (2010) 1.34
The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment Pharmacol Ther (2009) 1.25
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology (2008) 1.14
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil (2009) 1.14
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci (2011) 1.06
Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther (2010) 1.06
Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci (2009) 1.03
Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut (2010) 1.01
Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol (2012) 0.99
Medical management of constipation. Clin Colon Rectal Surg (2012) 0.96
Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther (2009) 0.95
Updates on treatment of irritable bowel syndrome. World J Gastroenterol (2008) 0.94
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype. BMC Gastroenterol (2010) 0.93
Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis (2009) 0.93
Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil (2011) 0.92
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci (2011) 0.91
Mechanisms of Electrical Activation and Conduction in the Gastrointestinal System: Lessons from Cardiac Electrophysiology. Front Physiol (2016) 0.90
Electrophysiological Mechanisms of Gastrointestinal Arrhythmogenesis: Lessons from the Heart. Front Physiol (2016) 0.89
Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway. J Neurogastroenterol Motil (2013) 0.89
New treatments for irritable bowel syndrome in women. Womens Health (Lond Engl) (2008) 0.88
Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol (2016) 0.88
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol (2014) 0.86
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health (2010) 0.85
Simplifying the measurement of gastric accommodation using SPECT. Neurogastroenterol Motil (2013) 0.84
Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol (2012) 0.83
Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging (2008) 0.82
What's New in the Toolbox for Constipation and Fecal Incontinence? Front Med (Lausanne) (2014) 0.81
Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therap Adv Gastroenterol (2011) 0.80
Selected interventions in nuclear medicine: gastrointestinal motor functions. Semin Nucl Med (2009) 0.80
Lubiprostone decreases the small bowel transit time by capsule endoscopy: an exploratory, randomised, double-blind, placebo-controlled 3-way crossover study. Gastroenterol Res Pract (2014) 0.80
A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients. Am J Gastroenterol (2016) 0.79
Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon. Korean J Physiol Pharmacol (2014) 0.79
Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis (2015) 0.78
Prokinetic effects of large-dose lubiprostone on gastrointestinal transit in dogs and its mechanisms. Am J Transl Res (2015) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Opioid-induced constipation: advances and clinical guidance. Ther Adv Chronic Dis (2016) 0.78
Recent advances in small bowel diseases: Part II. World J Gastroenterol (2012) 0.78
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol (2016) 0.78
New treatment options for chronic constipation: mechanisms, efficacy and safety. Can J Gastroenterol (2011) 0.77
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Lubiprostone: trials and tribulations. Nat Rev Gastroenterol Hepatol (2009) 0.77
May the truth be with you: lubiprostone as EP receptor agonist/ClC-2 internalizing "inhibitor". Dig Dis Sci (2012) 0.76
Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation. Clin Med Insights Gastroenterol (2012) 0.76
Role of lubiprostone on gastrointestinal motility. J Neurogastroenterol Motil (2013) 0.76
Management Strategies for Abdominal Bloating and Distension. Gastroenterol Hepatol (N Y) (2014) 0.76
Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies. Gastroenterol Hepatol (N Y) (2015) 0.75
Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence (2017) 0.75
Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. Am J Gastroenterol (2012) 0.75
Stimulation of Mucin, Mucus, and Viscosity during Lubiprostone in Patients with Chronic Constipation may Potentially Lead to Increase of Lubrication. Clin Transl Gastroenterol (2014) 0.75
A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Clin Interv Aging (2013) 0.75
Impaired viscosity of gastric secretion and its mucin content as potential contributing factors to the development of chronic constipation. Dig Dis Sci (2014) 0.75
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol (2017) 0.75
Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover study. Endosc Int Open (2017) 0.75
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
The digital rectal examination: a multicenter survey of physicians' and students' perceptions and practice patterns. Am J Gastroenterol (2012) 2.19
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93
Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93
Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology (2006) 1.91
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77
A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69
Increasing incidence of celiac disease in a North American population. Am J Gastroenterol (2013) 1.69
A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol (2005) 1.64
Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol (2007) 1.57
Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol (2007) 1.56
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Continuous 12-lead electrocardiographic monitoring in an emergency department chest pain unit: an assessment of potential clinical effect. Ann Emerg Med (2003) 1.54
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53
Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52
Symptoms and quality of life in community women with fecal incontinence. Clin Gastroenterol Hepatol (2006) 1.52
Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes (2013) 1.51
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Factors that predict relief from upper abdominal pain after cholecystectomy. Clin Gastroenterol Hepatol (2011) 1.50
Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol (2012) 1.47
A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol (2009) 1.47
Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46
Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol (2009) 1.46
Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes (2012) 1.46
Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol (2010) 1.46
Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr (2014) 1.45
American Gastroenterological Association medical position statement on constipation. Gastroenterology (2013) 1.44
Bowel disturbances are the most important risk factors for late onset fecal incontinence: a population-based case-control study in women. Gastroenterology (2010) 1.43
Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis (2009) 1.42
Phenotypic variation in functional disorders of defecation. Gastroenterology (2005) 1.41
Impact of gastroesophageal reflux on survival in the community. Am J Gastroenterol (2007) 1.40
Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol (2006) 1.39
Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.39
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology (2006) 1.39
Normal values for high-resolution anorectal manometry in healthy women: effects of age and significance of rectoanal gradient. Am J Gastroenterol (2012) 1.39
Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol (2008) 1.38
Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol (2011) 1.38
Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf) (2008) 1.37
The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis (2013) 1.36
Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology (2006) 1.35
A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.35
Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol (2012) 1.34
Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol (2011) 1.33